KITLG and soft tissue sarcoma: Pazopanib is a tyrosine kinase inhibitor of VEGF, platelet derived growth factor (PDGF) and stem cell factor (SCF)/c-KIT signalling, which is approved for the treatment of advanced soft tissue sarcoma.